Efficacy and Safety of Fezolamine in Depressed Patients
作者:
Sidney Zisook,
Joseph Mendels,
David Janowsky,
John Feighner,
John C.M. Lee,
Alan Fritz,
期刊:
Neuropsychobiology
(Karger Available online 1987)
卷期:
Volume 17,
issue 3
页码: 133-138
ISSN:0302-282X
年代: 1987
DOI:10.1159/000118353
出版商: S. Karger AG
关键词: Antidepressant medication;Efficacy;Fezolamine;Depressive disorder;major;Side effects
数据来源: Karger
摘要:
Forty-two outpatients with major depressive disorder were treated with oral fezolamine in a 6-week, three-center open-label study. Therapy was initated at 100 mg/day; thereafter dosage was increased based on the response of the patient. Maintenance dosage usually ranged between 100 and 450 mg/day. Clinically significant improvement relative to the patient’s prestudy state was observed after 2 weeks in both patient and physician-rating scales. Fifty-five percent of patients improved their Hamilton Psychiatric Rating Scale for Depression (HAM-D) scores by more than 50%. The median dose associated with a clinically significant response was 245 mg/day. Five of the 6 patients who dropped out did so because of gastrointestinal adverse effects. The most common adverse effects were nausea (36%), headache (29%), constipation (26%), and dry mouth (24%
点击下载:
PDF
(1140KB)
返 回